AbbVie Inc.ABBVNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank72
3Y CAGR-21.2%
5Y CAGR-14.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-21.2%/yr
vs -27.6%/yr prior
5Y CAGR
-14.9%/yr
Recent deceleration
Acceleration
+6.4pp
Accelerating
Percentile
P72
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
3 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 11.21% |
| Q3 2025 | 8.82% |
| Q2 2025 | 3.10% |
| Q1 2025 | -69.49% |
| Q4 2024 | 218.03% |
| Q3 2024 | 9.34% |
| Q2 2024 | 0.46% |
| Q1 2024 | -12.22% |
| Q4 2023 | 28.21% |
| Q3 2023 | -0.58% |
| Q2 2023 | -24.39% |
| Q1 2023 | 12.74% |
| Q4 2022 | 22.91% |
| Q3 2022 | -11.93% |
| Q2 2022 | 14.37% |
| Q1 2022 | -26.43% |
| Q4 2021 | 8.19% |
| Q3 2021 | 8.64% |
| Q2 2021 | 2.54% |
| Q1 2021 | -15.43% |
| Q4 2020 | 25.07% |
| Q3 2020 | -28.09% |
| Q2 2020 | 76.58% |
| Q1 2020 | -17.97% |
| Q4 2019 | -26.43% |
| Q3 2019 | 65.34% |
| Q2 2019 | -4.29% |
| Q1 2019 | -78.75% |
| Q4 2018 | 413.61% |
| Q3 2018 | 0.08% |
| Q2 2018 | 0.69% |
| Q1 2018 | -23.40% |
| Q4 2017 | 39.58% |
| Q3 2017 | -1.29% |
| Q2 2017 | 8.93% |
| Q1 2017 | -7.15% |
| Q4 2016 | 3.71% |
| Q3 2016 | -0.67% |
| Q2 2016 | 24.90% |
| Q1 2016 | -11.07% |